5FQR

Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 2.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.88 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.213 
  • R-Value Observed: 0.214 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.

Scott, J.S.Bailey, A.Davies, R.D.Degorce, S.L.Macfaul, P.A.Gingell, H.Moss, T.Norman, R.A.Pink, J.H.Rabow, A.A.Roberts, B.Smith, P.D.

(2016) ACS Med Chem Lett 7: 94

  • DOI: 10.1021/acsmedchemlett.5b00413
  • Primary Citation of Related Structures:  
    5FQP, 5FQR, 5FQS, 5FQT, 5FQV

  • PubMed Abstract: 
  • A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile. Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compounds with subnanomolar levels of potency. The phenol functionality was shown to be required to achieve highly potent compounds, but unusually this was compatible with obtaining high oral bioavailabilities in rat ...

    A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile. Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compounds with subnanomolar levels of potency. The phenol functionality was shown to be required to achieve highly potent compounds, but unusually this was compatible with obtaining high oral bioavailabilities in rat.


    Related Citations: 
    • Azd9496: An Oral Estrogen Receptor Inhibitor that Blocks the Growth of Er-Positive and Esr1-Mutant Breast Tumors in Preclinical Models.
      Weir, H.M., Bradbury, R.H., Lawson, M., Rabow, A.A., Buttar, D., Callis, R.J., Curwen, J.O., De Almeida, C., Ballard, P., Hulse, M., Donald, C.S., Feron, L.J.L., Karoutchi, G., Macfaul, P., Moss, T., Norman, R.A., Pearson, S.E., Tonge, M., Davies, G., Walker, G.E., Wilson, Z., Rowlinson, R., Powell, S., Sadler, C., Richmond, G., Ladd, B., Pazolli, E., Mazzola, A.M., D'Cruz, C., De Savi, C.
      (2016) Cancer Res 76: 3307

    Organizational Affiliation

    Oncology iMed, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
ESTROGEN RECEPTORA248Homo sapiensMutation(s): 4 
Gene Names: ESR1ESRNR3A1
UniProt & NIH Common Fund Data Resources
Find proteins for P03372 (Homo sapiens)
Explore P03372 
Go to UniProtKB:  P03372
PHAROS:  P03372
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP03372
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
QHG
Query on QHG

Download Ideal Coordinates CCD File 
B [auth A](E)-3-[4-[(1R)-6-HYDROXY-2-ISOBUTYL-3,4-DIHYDRO-1H-ISOQUINOLIN-1-YL]PHENYL]PROP-2-ENOIC ACID
C22 H25 N O3
PRJBEVDNTURUGU-YHEXHBFFSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
QHG BindingDB:  5FQR IC50: min: 4, max: 26 (nM) from 4 assay(s)
Binding MOAD:  5FQR IC50: 26 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.88 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.213 
  • R-Value Observed: 0.214 
  • Space Group: P 65 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 58.1α = 90
b = 58.1β = 90
c = 274.38γ = 120
Software Package:
Software NamePurpose
REFMACrefinement

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2016-02-10
    Type: Initial release
  • Version 1.1: 2016-10-12
    Changes: Database references